1,5-anhydroglucitol Blood Test More Accurate than HbA1c and Glucose for Predicting Mortality COVID-19 Patients with and without Diabetes

This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes. The study, “1,5-anhydroglucitol is an Independent Predictor of Mortality in Patients with COVID-19,” was presented at the American Heart Association (AHA) 2021 Scientific Sessions conference.

The study, conducted at Sinai Hospital in Baltimore, Md., showed that the GlycoMark® test had 76% mortality accuracy (AUC) compared to the accuracy for HbA1c and fasting glucose of 51% and 60%, respectively. The accuracy of GlycoMark was higher in patients without diabetes (79%) than in patients with diabetes (73%). An algorithm, which included age, BMI, and GlycoMark had an accuracy for prediction of mortality of 89%.

“We were pleased to find that the GlycoMark test identified mortality with high accuracy in COVID-19 patients,” says Paul Gurbel, MD, a cardiologist at the The LifeBridge Health Cardiovascular Institute and lead investigator of the trial. “GlycoMark may have utility in triaging COVID-19 patients in the hospital setting at higher risk of severity and mortality. This may be especially important in COVID-19 non-diabetic patients who may develop new-onset diabetes, which brings higher risks of severe disease and death.”

This study follows a previously reported study presented as a late-breaking abstract at the 2021 American Diabetes Association (ADA) Scientific Sessions, which showed that GlycoMark was an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients without diabetes. The study was conducted at Hospital Universitario Cruces in Bilbao, Spain.

You may also like

  • Islets in the Stream: Could Stem Cell Technology Be an Eventual Cure for Type 1 Diabetes?

    Recent studies have shown how stem cell-derived therapies have the potential as a renewable source of insulin-producing pancreatic islet cells. Promising as these results are, could stem cell technology eventually lead to a cure for diabetes as well as impacts well beyond endocrinology? Last December, two papers appeared in Cell Stem Cell and Cell Reports…

  • People with Diabetes and Cognitive Decline May Be at Higher Risk for Heart Disease

    People with type 2 diabetes who have cognitive impairment could be at greater risk for stroke, heart attack, or death than other individuals with diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Cognitive impairment is when a person has trouble remembering, learning new things, concentrating, or making…